Effects of a novel acylindole derivative on experimental thrombotic models, ulceration of the gastric mucosa and prostacyclin production in the aorta.
D000818:Animals; D001011:Aorta / Q000378:metabolism; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001792:Blood Platelets / Q000187:drug effects*; D011464:Epoprostenol / Q000096:biosynthesis*; D005343:Fibrinolytic Agents; D005753:Gastric Mucosa / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010974:Platelet Aggregation / Q000187:drug effects*; D011453:Prostaglandins / Q000096:biosynthesis*; D011817:Rabbits; D051381:Rats; D011919:Rats, Inbred Strains; D012772:Shock, Septic / Q000188:drug therapy; D013276:Stomach Ulcer / Q000139:chemically induced; D013927:Thrombosis / Q000188:drug therapy
D005343:Fibrinolytic Agents; D007211:Indoles; D011453:Prostaglandins; C033778:3-benzoyl-N-beta-ethoxyisopropyl-2-methylindole; D011464:Epoprostenol; D007213:Indomethacin